CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma

Ikeguchi, Ryotaro; Shimizu, Yuko; Shimizu, Satoru; Kitagawa, Kazuo

doi:10.1177/1352458517717804

Cited by 35 publications

(42 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The third study measured CSF levels and used a cut‐off value of 60·4 u/ml, resulting in a much higher sensitivity of 94·7% with a specificity of 84·6% (Sasagawa et al , ). Highest specificity (90%) of CSF IL‐2R was found by the fourth study, with a sensitivity of 83·3%, but no cut‐off value was reported (Ikeguchi et al , ).…”

Section: Resultsmentioning

confidence: 98%

“…The cut‐off values for CSF IL‐10 that delivered the highest accuracy varied strongly among the studies, between 3·0 and 21·77 pg/ml. Two other studies on IL‐10 did not report sensitivity and specificity, but did report a significant difference in the CSF IL‐10 concentrations between CNSL patients and controls (Ikeguchi et al , ; Salmaggi et al , ).…”

Section: Resultsmentioning

confidence: 99%

“…The diagnostic values of markers, as derived from the included studies, are listed for PCNSL (Table ) (Kersten et al , ; Murase et al , ; Roy et al , ; Baraniskin et al , , , ; Sasayama et al , ; Rubenstein et al , ; Mao et al , ; Kuusisto et al , ; Sasagawa et al , ; Viaccoz et al , ; Mabray et al , ; Nguyen‐Them et al , ; Song et al , ; Strehlow et al , ; Ikeguchi et al , ; Thaler et al , ) and for SCNSL (Table ) (Ernerudh et al , ; Kersten et al , ; Kara et al , ; Muñiz et al , ). Some of the included articles reported the diagnostic values for PCNSL and SCNSL as one patient group (Roy et al , ), these results are also included in Table .…”

Section: Resultsmentioning

confidence: 99%

“…All studies were at risk of bias, due to the risk of (i) bias in patient selection and (ii) bias introduced by post‐hoc threshold determination in the index test. Only nine studies reported on a consecutive sample of patients (Kersten et al , ; Baraniskin et al , , ; Kitai et al , ; Muñiz et al , ; Mabray et al , ; Nguyen‐Them et al , ; Ikeguchi et al , ; Thaler et al , ), therefore the remaining studies were at high or unclear risk of bias on this item. The study by Baraniskin et al () did not report how additional patients [above those already included in Baraniskin et al ()] were included, so the risk of bias in this study was scored as unclear.…”

Section: Resultsmentioning

confidence: 99%

“…The majority of patients was diagnosed with leukaemia, which did not correspond to the research question. Concerning the index test, only five studies (Ernerudh et al , ; Baraniskin et al , ; Kara et al , ; Sasagawa et al , ; Viaccoz et al , ) used pre‐specified cut‐off values in determining diagnostic value and seven studies (Mavligit et al , ; Salmaggi et al , ; Fischer et al , ; Kitai et al , ; Kuusisto et al , ; Baraniskin et al , ; Ikeguchi et al , ) did not use a threshold, but compared mean levels of the marker in patient and control group. Hence, risk of bias concerning the index test was high in the other thirteen studies.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review

et al. 2018

View full text Add to dashboard Cite

SummaryDiagnosing central nervous system (CNS) lymphoma remains a challenge. Most patients have to undergo brain biopsy to obtain tissue for diagnosis, with associated risks of serious complications. Diagnostic markers in blood or cerebrospinal fluid (CSF) could facilitate early diagnosis with low complication rates. We performed a systematic literature search for studies on markers in blood or cerebrospinal fluid for the diagnosis CNS lymphoma and assessed the methodological quality of studies with the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS‐2). We evaluated diagnostic value of the markers at a given threshold, as well as differences between mean or median levels in patients versus control groups. Twenty‐five studies were included, reporting diagnostic value for 18 markers in CSF (microRNAs ‐21, ‐19b, and ‐92a, RNU2‐1f, CXCL13, interleukins ‐6, ‐8, and ‐10, soluble interleukin‐2‐receptor, soluble CD19, soluble CD27, tumour necrosis factor‐alfa, beta‐2‐microglobulin, antithrombin III, soluble transmembrane activator and calcium modulator and cyclophilin ligand interactor, soluble B cell maturation antigen, neopterin and osteopontin) and three markers in blood (microRNA‐21 soluble CD27, and beta‐2‐microglobulin). All studies were at considerable risk of bias and there were concerns regarding the applicability of 15 studies. CXCL‐13, beta‐2‐microglobulin and neopterin have the highest potential in diagnosing CNS lymphoma, but further study is still needed before they can be used in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review

et al. 2018

View full text Add to dashboard Cite

show abstract

Multi‐marker algorithms based on CXCL13, IL‐10, sIL‐2 receptor, and β2‐microglobulin in cerebrospinal fluid to diagnose CNS lymphoma

et al. 2020

View full text Add to dashboard Cite

Tumor biopsy is essential for the definitive diagnosis of central nervous system (CNS) lymphoma. However, the biopsy procedure carries the risk of complications such as bleeding, convulsions, and infection. Cerebrospinal fluid (CSF) β2‐microglobulin (β2‐MG), soluble IL‐2 receptor (sIL‐2R), and interleukin‐10 (IL‐10) are known to be useful diagnostic biomarkers for CNS lymphoma. The C‐X‐C motif chemokine ligand 13 (CXCL13) was recently reported to be another useful biomarker for CNS lymphoma. The purpose of this study is to establish a diagnostic algorithm that can avoid biopsy by combining these diagnostic biomarkers. In the first, we conducted a case‐control study (n = 248) demonstrating that the CSF CXCL13 concentration was significantly increased in CNS lymphoma patients compared with various other brain diseases (AUC = 0.981). We established a multi‐marker diagnostic model using CSF CXCL13, IL‐10, β2‐MG, and sIL‐2R from the results of the case‐control study and then applied the model to a prospective study (n = 104) to evaluate its utility. The multi‐marker diagnostic algorithms had excellent diagnostic performance: the sensitivity, specificity, positive predictive value, and negative predictive value were 97%, 97%, 94%, and 99%, respectively. In addition, CSF CXCL13 was a prognostic biomarker for CNS lymphoma patients. Our study suggests that multi‐marker algorithms are important diagnostic tools for patients with CNS lymphoma.

show abstract

Cytokines: Application in recurrence appraisal for differentiated thyroid carcinoma and their relation with radioiodine ablation

Yang

Yin

Zhang

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

The limitations in discriminating preablation disease-active status of differentiated thyroid carcinoma (DTC) still represent a major challenge to radioiodine dose management. Cytokines, the small protein signaling molecules that constitute the thyroid tumor microenvironment, play significant roles in the facilitation of intercellular communication and the control of tumorigenesis. Also, more attention should be paid to the molecular events within the innate and adaptive immune systems that occur after the organism being exposed to ionizing radiation. Therefore, we implemented a study of 260 patients with DTC in thyroid hormone withdrawal status who were treated with total thyroidectomy to explore the relationship between cytokines and recurrence/active disease status. Besides, we made a cross-sectional study to analyze pre-and post-ablation serum concentration of cytokines of 86 patients with DTC. There was a relationship between clinicohistopathological characteristics of patients with DTC and the presence of cytokines. It is noteworthy that patients with recurrence/active disease were at a higher serum interleukin-2 receptor (IL-2R) level than the disease-free patients (213.59 ± 75.43 pg/ml vs.186.80 ± 77.40 pg/ml, P = 0.005). Positive correlation was observed between serum IL-2R and thyroglobulin (Tg) (P = 0.003). We also found significant changes in the cytokine profile after radioiodine ablation, including the decrease of tumor necrosis factor-α and IL-8 (P < 0.001, P < 0.001, respectively), and increase of IL-2R (P < 0.001). Thus, we suggest that serum IL-2R may assist in evaluating the disease status during the post-thyroidectomy follow-up and radioiodine therapy has an immunoregulatory effect on serum cytokines. K E Y W O R D Scytokines, differentiated thyroid carcinoma, interleukin-2 receptor (IL-2R), radioiodine ablation Mengdie Yang, Yuzhen Yin, and Jiajia Zhang should be considered joint first author.

show abstract

CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma

Abstract: CSF sIL-2R levels can be used to differentiate CNS lymphoma from CNS IDDs. Further studies may identify other applications of CSF as a diagnostic biomarker.

Cited by 35 publications

References 36 publications

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review

Multi‐marker algorithms based on CXCL13, IL‐10, sIL‐2 receptor, and β2‐microglobulin in cerebrospinal fluid to diagnose CNS lymphoma

Cytokines: Application in recurrence appraisal for differentiated thyroid carcinoma and their relation with radioiodine ablation

Contact Info

Product

Resources

About